Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Inclusion Criteria: * Ability to understand and the willingness to provide informed consent * Pathologically well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2). * Primary tumor location should be known or believed to be midgut. * At least one tumor in the liver that is positive with \[68\]Ga-DOTATATE (NETSPOT). Imaging must be performed within the past 6 months. * Liver lesions not amendable to other therapies (surgery, ablation) and have progressed after treatment with octreotide/lanreotide and/or other treatments. (everolimus, sunitinib). * Karnofsky performance status of at least 70 * Absolute neutrophil count of at least 1,000 cells/mm3 * Platelet count of at least 90,000 cells / mm3 * Total bilirubin ≤ 2 x the upper limit of normal when adjusted for age * AST and ALT ≤ 5 x the upper limit of normal when adjusted for age * Serum creatinine ≤ 1.2 mg/dl; if serum creatinine is \>1.2 mg/dl nuclear GFR will used for potentially eligible participants. * Agrees to contraception. Exclusion criteria: * Liver tumor involvement greater than 70% by cross sectional imaging * Extra-hepatic visceral and osseous metastases * Concomitant therapy for tumor (except for somatostatin analogs or bisphosphonates) * Previous PRRT or other liver directed therapy within 12 months of consent * Women who are pregnant, breast feeding or breast pumping. * Another concurrent malignancy on active therapy * Previous external-beam radiation therapy to a kidney (including scatter dose) * Therapeutic investigational drug within 4 weeks of therapy. * Subjects for whom, in the opinion of their physician, a 24-hour discontinuation of somatostatin analogue therapy represents a health risk. * Sandostatin LAR injection within 4 weeks or lanreotide injection within 8 weeks of proposed therapy. * Inability to lie down supine for study procedure. * Reaction to IV contrast used for the angiogram. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements